Introduction {#s1}
============

The emergence of *Candida auris* has received worldwide attention, not only from the scientific and clinical communities, but has as well been picked up by several public media channels. *C. auris* being reported as a 'sometimes deadly and often resistant fungal infection', 'a superbug highly resistant to traditional drugs' and '*C. auris* sickens dozens', makes clear that there is something to be feared from this newly recognised *Candida* species.

The yeast *C. auris* was described for the first time in 2009 on recovery from the external ear canal of a Japanese patient.[@R1] Subsequently, *C. auris* was recognised as causing chronic otitis media in 15 patients in Korea, including three paediatric patients.[@R2] The earliest case to date was identified in retrospect by DNA sequencing of a Korean bloodstream isolate from a paediatric surgery patient in 1996.[@R3] Since 2009, patients colonised and infected with *C. auris* have been reported from nearly all continents (except for Australia and Antarctica). *C. auris* has been shown to be a challenge to identify and treat, is capable to cause difficult to manage hospital outbreaks and reasons for its emergence is far from clear.[@R4]

The vast majority of infections caused by *Candida* species in the paediatric population are caused by *C. albicans* or *C. parapsilosis*, while the more antifungal resistant species as *C. glabrata* and *C. krusei* are less prevalent in comparison to *Candida* infections in adult patients.[@R6] As the very first reports of *C. auris* infections are described in both neonates and children as well as adults, attention needs to be paid to its consequences for the management of *Candida* infections in the paediatric population.

Clinical epidemiology {#s2}
=====================

A literature search, restricted to publications in English, including publications up to 8 December 2017, was performed by using Medline/Pubmed. At that moment, published clinical reports of *C. auris* infections originated from Japan, South Korea, India, Kuwait, Oman, South Africa, Venezuela, Panama, Colombia, Pakistan, Israel, Spain, UK, Canada and the USA describing 109 patients with candidaemia, 19 patients with chronic otitis media or otitis externa and 28 patients with other infections (including candiduria/urinary tract infections (n=16) and wound and soft tissue infections (n=6)).[@R1] Real-time data from the Centers for Disease Control and Prevention show that new cases are reported on an almost weekly basis with a total of 243 clinical cases of *C. auris* infection in the USA.[@R22] Public Health England shows a more episodic pattern in reported clinical cases (56 in total) with high increases during outbreaks.[@R23] No paediatric patients have been reported in the UK (Dr E M Johnson, Public Health England, personal communication).

Ten out of the 18 publications described infections in adult patients only. Two publications did include paediatric patients but no details were given separately for the patients \<18 years of age[@R19] or age was not mentioned.[@R13] Twenty-three paediatric patients have been reported in five case series published, of which 20 neonates and children suffered from a blood stream infection (18% of the total population).[@R3] Three other paediatric patients suffered from chronic otitis media with positive ear swabs for *C. auris*.[@R2] [Table 1](#T1){ref-type="table"} summarises the clinical characteristics of those infections. Paediatric patients have only been reported in Asia and South America. Underlying conditions and risk factors are comparable to those known to render paediatric patients at risk for developing candidaemia and invasive candidiasis. Of the 20 paediatric patients with candidaemia due to *C. auris*, 14 were neonates and/or born prematurely. Older infants and children developed *C. auris* candidaemia during intensive care unit (ICU) admissions, postsurgery or with an underlying haematological malignancy. Antifungal regimens prescribed varied hugely with half of the patients receiving combination antifungal therapy with two or three antifungals. Mortality was 30% in paediatric patients with *C. auris* blood stream infections and lower compared with adult patients with mortality rates ranging from 30% to 60%. In contrast, during the *C. auris* outbreak in a large UK hospital, no attributable deaths were observed due to *C. auris* infections.[@R4]

###### 

Clinical epidemiology of published paediatric cases with *Candida auris* infections

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient number (reference)    Country       Sex/age         Underlying condition                                                        Positive cultures   Localisation of infection   Treatment                 Outcome
  ----------------------------- ------------- --------------- --------------------------------------------------------------------------- ------------------- --------------------------- ------------------------- ----------
  1 (Lee *et al* [@R3])         South Korea   F/1 year        Traumatic respiratory arrest\                                               Blood               Blood stream                FLU, removal CVC          Survived
                                                              Aspiration pneumonia                                                                                                                                  

  2 (Chowdhary *et al* [@R8])   India         F/3 days        Prematuritas, TEF, ICH, bacterial sepsis                                    Blood               Blood stream                Caspo                     Died

  3 (Chowdhary *et al* [@R8])   India         F/10 days       Prematuritas, ELBW, bacterial sepsis                                        Blood               Blood stream                d-AmB                     Survived

  4 (Chowdhary *et al* [@R8])   India         F/28 days       Pneumonia, late-onset sepsis                                                Blood               Blood stream                d-AmB                     Survived

  5 (Chowdhary *et al* [@R8])   India         F/45 days       Meningitis, septic shock, cardiac defect                                    Blood               Blood stream                d-AmB                     Survived

  6 (Chowdhary *et al* [@R8])   India         M/10 years      ALL, chronic kidney disease                                                 Blood               Blood stream                none                      Died

  7 (Chowdhary *et al* [@R9])   India         M/2 years       Short-bowel syndrome, intestinal perforation, pneumonia, bacterial sepsis   Blood,\             Blood stream                FLU, d-AmB, removal CVC   Survived
                                                                                                                                          tip CVC                                                                   

  8 (Calvo *et al* [@R12])      Venezuela     F/30 days       Prematuritas, sepsis                                                        Blood               Blood stream                AmB, VORI                 Died

  9 (Calvo *et al* [@R12]       Venezuela     F/13 days       Prematuritas, colon atresia, sepsis, abdominal surgery                      Blood               Blood stream                VORI, AmB, Caspo          Died

  10 (Calvo *et al* [@R12])     Venezuela     M/17 days       Abdominal surgery, sepsis                                                   Blood               Blood stream                FLU                       Died

  11 (Calvo *et al* [@R12])     Venezuela     F/23 days       Prematuritas, septic shock                                                  Blood               Blood stream                Caspo                     Survived

  12 (Calvo *et al* [@R12])     Venezuela     M/18 days       Prematuritas, sepsis                                                        Blood               Blood stream                FLU, VORI, Caspo          Died

  13 (Calvo *et al* [@R12])     Venezuela     M/2 days        Intestinal atresia, congenital heart disease, abdominal surgery             Blood               Blood stream                Caspo                     Survived

  14 (Calvo *et al* [@R12])     Venezuela     M/12 days       NEC, HIE, sepsis, abdominal surgery                                         Blood               Blood stream                VORI, Caspo               Survived

  15 (Calvo *et al* [@R12])     Venezuela     M/11 days       Prematuritas, NEC, sepsis, abdominal surgery                                Blood               Blood stream                AmB, Caspo                Survived

  16 (Calvo *et al* [@R12])     Venezuela     F/18 days       Prematuritas, abdominal wall defect, sepsis, abdominal surgery              Blood               Blood stream                VORI                      Survived

  17 (Calvo *et al* [@R12])     Venezuela     F/14 years      Septic shock                                                                Blood               Blood stream                VORI, Anidula, Caspo      Survived

  18 (Calvo *et al* [@R12])     Venezuela     F/10 days       Prematuritas, HIE, sepsis                                                   Blood               Blood stream                FLU                       Survived

  19 (Calvo *et al* [@R12])     Venezuela     F/2 months      Meningocele, congenital hydrocephalus, sepsis                               Blood               Blood stream                VORI, Caspo               Survived

  20 (Calvo *et al* [@R12])     Venezuela     M/1 month       Prematuritas, RDS, sepsis                                                   Blood               Blood stream                VORI, Caspo               Survived

  21 (Kim *et al* [@R2])        Korea         Not available   Chronic otitis media                                                        Ear                 Ear                         n.a.                      Survived

  22 (Kim *et al* [@R2])        Korea         Not available   Chronic otitis media                                                        Ear                 Ear                         n.a.                      Survived

  23 (Kim *et al* [@R2])        Korea         Not available   Chronic otitis media                                                        Ear                 Ear                         n.a.                      Survived
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALL, acute lymphoblastic leukaemia; AmB, amphotericin B; anidula, anidulafungin; caspo, caspofungin; CVC, central vascular catheter; d-AMB, amphotericin deoxycholate; ELBW, extreme low-birth weight; HIE, hypoxic ischaemic encephalopathy; ICH, intracerebral haemorrhage; FLU, fluconazole; NEC, necrotising enterocolitis; RDS, respiratory distress syndrome; TEF, trachea o esophageal fistula; VORI, voriconazole.

As *C. auris* has been commonly misidentified as *Candida haemulonii*, a rare encountered *Candida* species causing invasive infections.[@R3] Paediatric patients with *C. haemulonii* blood stream infections reported in the literature have been summarised in [table 2](#T2){ref-type="table"}. The clinical characteristics are comparable to those described for *C. auris* fungaemia and neonates and children with well-known underlying conditions and risk factors to develop invasive fungal disease are affected. Thirteen paediatric patients from Kuwait, Korea and Brazil have been described, including five premature neonates.[@R2] *C. haemulonii* infections have been more often described in infants and children (62%) compared with *C. auris* infections affecting mostly neonates (70%). Half of the patients with *C. haemulonii* infections were treated with combination antifungal therapy and the mortality rate was 30%.

###### 

Clinical epidemiology of published paediatric cases with fungaemia caused by *Candida haemulonii* and *Candida pseudohaemulonii*

  Patient number (reference)   Country   Sex/age       Underlying condition                                     Candida species         Treatment           Outcome
  ---------------------------- --------- ------------- -------------------------------------------------------- ----------------------- ------------------- ----------
  1 (Khan *et al* [@R24])      Kuwait    M/6 weeks     Prematuritas, hernia diaphragmatica                      *C. haemulonii*         L-AmB, Caspo, FLU   Died
  2 (Khan *et al* [@R24])      Kuwait    M/10 weeks    Prematuritas, ELBW                                       *C. haemulonii*         FLU                 Survived
  3 (Khan *et al* [@R24])      Kuwait    F/7 weeks     Prematuritas, ELBW                                       *C. haemulonii*         d-AmB, Caspo        Survived
  4 (Khan *et al* [@R24])      Kuwait    F/1 month     Prematuritas, LBW                                        *C. haemulonii*         L-AmB               Died
  5 (Kim *et al* [@R2])        Korea     M/10 years    Nasopharyngeal cancer, upper gastrointestinal bleeding   *C. haemulonii*         ITRA, d-AmB, FLU    Survived
  6 (Kim *et al* [@R2])        Korea     M/10 months   Necrotising enterocolitis                                *C. pseudohaemulonii*   FLU                 Survived
  7 (Kim *et al* [@R2])        Korea     M/2 years     Acquired combined immunodeficiency                       *C. pseudohaemulonii*   d-AmB               Died
  8 (Kim *et al* [@R2])        Korea     F/2 months    Necrotising enterocolitis                                *C. pseudohaemulonii*   FLU, d-AmB, L-AmB   Survived
  9 (Kim *et al* [@R2])        Korea     F/12 months   Cardiac defect                                           *C. pseudohaemulonii*   L-AmB, FLU          Died
  10 (Kim *et al* [@R2])       Korea     F/2 years     Cardiac defect                                           *C. pseudohaemulonii*   FLU                 Survived
  11 (Muro *et al* [@R25])     Brazil    F/19 months   Down syndrome, cardiac surgery, chylothorax              *C. haemulonii*         d-AmB, L-AmB, FLU   Survived
  12 (Muro *et al* [@R25])     Brazil    F/9 years     Ewing's sarcoma, febrile neutropaenia                    *C. haemulonii*         d-AmB               Survived
  13 (Silva *et al* [@R26])    Brazil    F/3 weeks     Prematuritas, ELBW                                       *C. haemulonii*         FLU                 Survived

Caspo, caspofungin; d-AMB, amphotericin deoxycholate; ELBW, extreme low birth weight; FLU, fluconazole; L-AmB, liposomal amphotericin B; LBW, low birth weight; ITRA, itraconazole.

Due to the low numbers of paediatric patients described, it is difficult to draw meaningful comparisons with *Candida* infections caused by other species, specific patient groups affected, geographic patterns and the outcome of the infections.

Identification and susceptibility {#s3}
=================================

*C. auris* isolates have been misidentified as a range of other *Candida* species by using conventional phenotypic and biochemical methods. Most commonly, these isolates have been misidentified as *C. haemulonii*, as *C. auris* is phylogenetically closely related to the *C. haemulonii* species complex.[@R3] *C. haemulonii* complex species are less frequently detected than *C. auris*, although inaccuracies with the molecular identification of less common *Candida* species prevents a robust insight into these infections.[@R5] It is also possible that some of the reported isolates of *C. haemulonii* are misidentified as *C. auris*. It has been suggested that chromogenic agar is a low-cost method to differentiate between *C. auris* and *C. haemulonii* isolates.[@R5] Molecular techniques are recommended to identify *C. auris* to the species level. Matrix-assisted laser desorption ionisation--time of flight mass spectrometry is capable of providing an accurate identification to the species level once spectra for *C. auris* are present in its database.[@R5] The development of *C. auris-*specific PCR assays allows for rapid identification and are of particular use during outbreak settings.[@R5] Sequencing of genetic loci and internal transcribed spacer domains of the rRNA provides the ability to differentiate between geographic clades.[@R5] Genome sequencing has been shown to be useful in the identification of *C. auris* but is often not an available technique in most laboratories and is less feasible for routine identification purposes.

Intrinsic susceptibility patterns for *C. auris* show elevated minimum inhibitory concentrations for all three classes of antifungals, the polyenes, the azoles and the echinocandins.[@R27] Exact breakpoints as have been established for the common *Candida* species using the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing methodologies have not been established.[@R28] Antifungal susceptibility data for 54 *C. auris* isolates showed that 93% were resistant to fluconazole (≥32 mg/L), 54% to voriconazole (≥2 mg/L), 35% to amphotericin B (≥2 mg/L) and 7% to echinocandins (≥8 mg/L).[@R3] Forty-one per cent of those isolates were resistant to greater than or equal to two classes of antifungals. Resistance to all three classes of antifungals was observed in two Indian isolates.[@R21] Of the 13 *C. haemulonii* infections in paediatric patients, eight isolates (62%) showed amphotericin B resistance, two isolates (15%) showed resistance for fluconazole and two (15%) for echinocandins.[@R2]

Emergence of *C. auris* {#s4}
=======================

Results from whole-genome sequencing studies suggest that *C. auris* has emerged near simultaneously in four or more locations rather than spreading from a single source.[@R21] Sequencing of *C. auris* isolates in the UK have clearly shown that those isolates have several geographic origins and belong to at least three different clades.[@R29] This suggest that *C. auris* isolates have been introduced into the UK from different locations.

But what has driven the emergence of this new *Candida* species? One of the explanations could be that *C. auris* has just not been recognised before, but this is not supported by retrospective reviews of large collections of *Candida* isolates. A thorough review of over 15 000 *Candida* isolates from four continents (SENTRY isolate collection) did not detect any *C. auris* isolate before 2009.[@R21] Increasing antifungal selection pressures either in humans and/or animals and/or the environment may cause the emergence of a new multidrug-resistant *Candida* species. The availability of antifungals with an improved toxicity profile has contributed to an expansion in the prescriptions of antifungals for prophylactic and empirical use. Increased antifungal use in agriculture and in the clinical environment has led to well-recognised emerging resistance among *Aspergillus fumigatus* (azole resistance) and *C. glabrata* (echinocandin resistance).[@R30] However, selection by antifungal pressure alone seems to be less likely as non-*albicans Candida* species have been increasing since the introduction of fluconazole in 1990. Changes to the ecological niches of *C. auris* and intrinsic characteristics as numerous virulence attributes, thermotolerance and salt tolerance and aggregation into difficult-to-disperse clusters, may have allowed the emergence of this newly recognised species causing human infections and persistence in hospital environments.[@R31] A number of molecular resistance mechanisms are well described for causing resistance to particular antifungals in several *Candida* species.[@R28] As yet, molecular mechanisms resulting in antifungal resistance in *C. auris* need to be elucidated.

Clinical management {#s5}
===================

Based on susceptibility data, echinocandins seem to be the drug of choice as less than 10% resistance is reported.[@R27] Micafungin showed increased efficacy in a murine study of *C. auris* candidaemia compared with fluconazole and amphotericin B.[@R32] For the paediatric population, micafungin and caspofungin can be used while awaiting susceptibility testing results.[@R33] Depending on the site of infection, alternative choices might be considered.[@R5] Echinocandins have limited penetration in the cerebrospinal fluid and urine, and therefore other antifungal compounds should be used to treat central nervous system or renal tract infections.[@R35] No recommendations can be made with regard to treatment with combinations of antifungals, as data are not available.

Consideration should be given to determine *Candida* isolates from mucosal surfaces and non-sterile sites to the species level and perform susceptibility testing. Particularly, in paediatric patients at high risk for developing invasive *Candida* infections, as these results may guide early and targeted treatment if a *Candida* infection is suspected based on clinical signs and symptoms. Even more so in premature neonates where a high percentage of false-negative blood cultures for *Candida* species has been described.[@R36]

An additional reason to be informed about colonising *C. auris* isolates in intensive care settings is to prevent transmission and to instal proper infection prevention and control measures. Several countries including the UK have released guidance documents with recommendations regarding screening policies, isolation of patients, contact precautions and cleaning of equipment and clinical environments.[@R5]

Summary {#s6}
=======

*C. auris* infections have emerged as an important challenge in the management of already vulnerable paediatric patients including premature neonates, infants and children admitted to ICUs and those with underlying malignancies. Proper identification is challenging with conventional methodologies failing. Great concern exists how to control this emerging new *Candida* species showing multidrug resistance and being very well capable to persist in hospital environments. The increased number of cases detected worldwide is causing a global concern and research is urgently needed. Current research is addressing the many unanswered questions related to the emergence of this *Candida* species, its molecular resistance and virulence mechanisms and improved management options to minimise its impact on patient outcomes.
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